[Acute disseminated XXXX in Tunisia: Report of a pediatric cohort].

@entity1 @entity1667 @entity6220 @entity16 @entity1651 @entity21 @entity2287 @entity15 @entity479
INTRODUCTION: Acute disseminated @entity1651 (ADEM) is an inflammatory, demyelinating @entity6220 whose clinical features, management and outcome are incompletely understood in Tunisian population. OBJECTIVE: To describe clinical, neuroimaging and laboratory features; treatment and outcome in a cohort of Tunisian @entity1 with ADEM. METHODS: We conducted a retrospective review of the medical records of all @entity1 attending the Department of @entity1 and Adolescent Neurology (Tunis) with ADEM between 2005 and 2015. Clinical, neuroimaging and laboratory features, therapeutic data and outcome were analyzed. RESULTS: There were 15  @entity1 (7  males and 8  females). The mean age at onset was 6.9years. Thirteen (86.6%) @entity1 had a prodromal event. The onset of @entity16 occurred within 17.6days (4-30). Limb weakness was the most common presenting symptom (53.3%). @entity21 was noticed in 6  @entity1 (40%). Initial MRI showed a deep gray matter involvement in 7  cases (46.6%). @entity2287 enhancement at acute stage was observed in only 2  @entity1 (13%). Cerebrospinal fluid findings did not show intrathecal oligoclonal bands. The use of high-dose IV @entity1667 followed by oral @entity479 taper was associated with rapid recovery. Additional treatment with intravenous immunoglobulin was necessary in 2  @entity1 . Complete recovery was obtained in 11  @entity1 (73.3%). A monophasic course was noticed in 14  cases. Only one @entity1 (5%) developed @entity15 . CONCLUSION: The high frequency of prodromal events and @entity21 in addition to the low rate of @entity2287 enhancement at acute stage seem to be the main features in our @entity1 . Larger ADEM multicenter cohort studies in Tunisia and North Africa could provide more detailed information about this entity.
